Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline... see more

Add To Watchlist

Recent & Breaking News (PINL:ZLDPF)

Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022

GlobeNewswire May 5, 2022

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

GlobeNewswire April 22, 2022

Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022

GlobeNewswire April 7, 2022

Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

GlobeNewswire April 7, 2022

Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2022

Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations

GlobeNewswire March 30, 2022

Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

GlobeNewswire March 11, 2022

Zealand Pharma convenes its Annual General Meeting 2022

GlobeNewswire March 10, 2022

Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

GlobeNewswire March 10, 2022

Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021

GlobeNewswire March 3, 2022

Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022

GlobeNewswire February 25, 2022

Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)

GlobeNewswire February 15, 2022

Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

GlobeNewswire January 20, 2022

Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022

GlobeNewswire January 19, 2022

Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

GlobeNewswire January 3, 2022

Total number of shares and voting rights in Zealand Pharma at December 30, 2021

GlobeNewswire December 30, 2021

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

GlobeNewswire December 16, 2021

Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital

GlobeNewswire December 14, 2021

Total number of shares and voting rights in Zealand Pharma at November 30, 2021

GlobeNewswire November 30, 2021

Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide

GlobeNewswire November 22, 2021